摘要
目的:观察清心解瘀方治疗稳定性冠心病的疗效及对细胞锚蛋白1(ANK1)、血清CD40配体(CD40L)的影响。方法:将稳定性冠心病患者134例分为2组。对照组在常规治疗基础上加服安慰剂,观察组在常规治疗基础上加服清心解瘀方治疗,分析2组患者治疗后的临床疗效及临床结局,监测ANK1、CD40L、角蛋白8(KRT8)。结果:观察组总有效率为80.60%,高于对照组的64.18%,差异有统计学意义(P<0.05)。治疗前,2组ANK1、CD40L、KRT8水平比较,差异无统计学意义(P>0.05)。2组治疗后均较前改善,观察组治疗后ANK1、CD40L、KRT8水平低于对照组(P<0.05)。观察组主要复合终点事件发生率1.49%,低于对照组的10.45%,2组比较,差异有统计学意义(P<0.05)。观察组次要复合终点事件发生率为1.49%,与对照组(4.48%)比较,差异无统计学意义(P>0.05)。结论:清心解瘀方治疗稳定性冠心病可调节患者体内ANK1、CD40L、KRT8的表达水平,降低患者终点事件发生率,提高疗效。
Objective:To observe the therapeutic effect of Qingxin Jieyu prescription on stable coronary heart disease and its effect on ankyrin 1(ANK1) and CD40 ligand(CD40 L). Methods:A total of 134 patients with stable coronary heart disease were divided into two groups. The control group was treated with placebo based on conventional treatment, and the observation group was treated with Qingxin Jieyu prescription based on conventional treatment. The clinical effect and outcome of the two groups were analyzed,and the levels of ANK1, CD40 L and keratin 8(KRT8) were monitored. Results:The total effective rate was 80.60% in the observation group, higher than that of 64.18% in the control group,the difference being significant(P<0.05). Before treatment,there was no significant difference in the comparison of the levels of ANK1,CD40 L and KRT8 between the two groups(P>0.05). The levels of ANK1,CD40 L and KRT8 in both groups were improved when respectively compared with those before treatment, and those in the observation group were lower than those in the control group(P<0.05). The incidence of major composite endpoint events was 1.49% in the observation group, lower than that of 10.45% in the control group(P<0.05). The incidence of secondary composite endpoint events was 1.49% in the observation group, lower than that of 4.48% in the control group, there being no significant difference(P>0.05).Conclusion: Qingxin Jieyu prescription for stable coronary heart disease, can regulate the expression levels of ANK1,CD40 L and KRT8 in patients, reduce the incidence of composite endpoint events, and improve the curative effect.
作者
王贞
张志国
张君
WANG Zhen;ZHANG Zhiguo;ZHANG Jun
出处
《新中医》
CAS
2020年第17期51-54,共4页
New Chinese Medicine
基金
河南省中医管理局国家中医临床研究基地科研专项项目(2018JDZX101)。
